Key Points
- Roivant Sciences director Melissa Epperly sold 17,750 shares on June 29 at an average price of $34.38, for total proceeds of $610,245. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Epperly held 16,474 shares valued at about $566,376, representing a 51.86% reduction in her position.
- The company recently beat quarterly EPS expectations, and analysts remain broadly positive with a Moderate Buy consensus and an average price target of $33.59, while the stock was trading near its 52-week high.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Melissa Epperly sold 17,750 shares of the business's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.38, for a total transaction of $610,245.00. Following the transaction, the director owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Roivant Sciences Stock Down 1.0%
Shares of NASDAQ ROIV opened at $35.03 on Thursday. The firm has a market cap of $25.20 billion, a PE ratio of -58.38 and a beta of 1.10. The company's fifty day simple moving average is $30.00 and its 200 day simple moving average is $27.11. Roivant Sciences Ltd. has a 12-month low of $10.70 and a 12-month high of $35.90.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The firm had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. During the same period in the previous year, the firm posted ($0.29) earnings per share. On average, equities analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. TD Cowen boosted their target price on Roivant Sciences from $38.00 to $41.00 and gave the company a "buy" rating in a research report on Thursday, May 21st. HC Wainwright reiterated a "buy" rating and issued a $34.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Citigroup raised their price objective on Roivant Sciences from $35.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, May 21st. Guggenheim boosted their price objective on Roivant Sciences from $30.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, May 26th. Finally, Sanford C. Bernstein initiated coverage on Roivant Sciences in a research report on Friday, March 20th. They set an "outperform" rating and a $35.00 target price on the stock. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $33.59.
Get Our Latest Stock Analysis on ROIV
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. increased its position in shares of Roivant Sciences by 37.1% during the first quarter. Pacer Advisors Inc. now owns 96,303 shares of the company's stock worth $2,668,000 after acquiring an additional 26,044 shares in the last quarter. Empowered Funds LLC lifted its position in Roivant Sciences by 1,468.5% in the 1st quarter. Empowered Funds LLC now owns 285,915 shares of the company's stock valued at $7,920,000 after acquiring an additional 267,686 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in Roivant Sciences in the 1st quarter valued at about $3,550,000. Parallel Advisors LLC boosted its stake in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock valued at $57,000 after purchasing an additional 520 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its stake in Roivant Sciences by 3.8% during the 1st quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company's stock valued at $229,507,000 after purchasing an additional 300,000 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
